Novo's once-weekly insulin hope on par with daily injections, phase III trials show

Novo Nordisk has announced headline results from two late-stage studies of its once-weekly insulin treatment, insulin icodec, meeting both endpoints.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by christian bundgaard, translated by daniel pedersen

On Friday, Novo Nordisk announced clinical success with its once-weekly insulin icodec in two different studies, according to a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading